Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity

NCT07120828 is registered in ClinicalTrials.gov with Erbil Polytechnic University as lead sponsor.

NCT NCT07120828
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07120828 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity
Lead sponsor
Erbil Polytechnic University
Phase
Phase 4
Overall status
Completed
Start date
July 15, 2025
Completion date
March 15, 2026
Enrollment
260 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obese diabetics, obese patients (bmi ≥ 30 kg/m²), type 2 diabetes